Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Francis W. Nugent"'
Autor:
Keith Stuart, Dan G. Duda, Francis W. Nugent, Rakesh K. Jain, Marek Ancukiewicz, Yihuan Xu, Rebecca R. Hozak, Adarsh Joshi, Rita P. Dalal, Jonathan D. Schwartz, Weijing Sun, Jayne Gurtler, Mary Mulcahy, Richard S. Finn, Andrew X. Zhu
PDF file - 23K, Waterfall plot depicting the percent change from baseline in serum in alphafetoprotein (AFP)and treatment response in HCC patients after ramucirumab monotherapy. PR, partial response; SD, stable disease; PD, progressive disease; NE, n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01898f20796700e6a757533a0e57e988
https://doi.org/10.1158/1078-0432.22448430
https://doi.org/10.1158/1078-0432.22448430
Autor:
Keith Stuart, Dan G. Duda, Francis W. Nugent, Rakesh K. Jain, Marek Ancukiewicz, Yihuan Xu, Rebecca R. Hozak, Adarsh Joshi, Rita P. Dalal, Jonathan D. Schwartz, Weijing Sun, Jayne Gurtler, Mary Mulcahy, Richard S. Finn, Andrew X. Zhu
PDF file - 65K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b58066f9cdbc357023863f22d351570e
https://doi.org/10.1158/1078-0432.22448424
https://doi.org/10.1158/1078-0432.22448424
Autor:
Keith Stuart, Dan G. Duda, Francis W. Nugent, Rakesh K. Jain, Marek Ancukiewicz, Yihuan Xu, Rebecca R. Hozak, Adarsh Joshi, Rita P. Dalal, Jonathan D. Schwartz, Weijing Sun, Jayne Gurtler, Mary Mulcahy, Richard S. Finn, Andrew X. Zhu
PDF file - 76K, Fold changes in biomarker levels relative to baseline following ramucirumab infusion across study cycles. Each line indicates values for a single patient.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5375d82eda6c0d701ce99f30037a4f76
https://doi.org/10.1158/1078-0432.22448427
https://doi.org/10.1158/1078-0432.22448427
Autor:
Keith Stuart, Dan G. Duda, Francis W. Nugent, Rakesh K. Jain, Marek Ancukiewicz, Yihuan Xu, Rebecca R. Hozak, Adarsh Joshi, Rita P. Dalal, Jonathan D. Schwartz, Weijing Sun, Jayne Gurtler, Mary Mulcahy, Richard S. Finn, Andrew X. Zhu
PDF file - 91K, Table S1.Fold changes in serum biomarkers relative to baseline following ramucirumabtreatment (MGH lab) Table S2: Changes in serum biomarkers relative to baseline following ramucirumab treatment (ImClonelab).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cc9b2b7500338f166849eda6e0ab3b6
https://doi.org/10.1158/1078-0432.22448421.v1
https://doi.org/10.1158/1078-0432.22448421.v1
Autor:
Keith Stuart, Dan G. Duda, Francis W. Nugent, Rakesh K. Jain, Marek Ancukiewicz, Yihuan Xu, Rebecca R. Hozak, Adarsh Joshi, Rita P. Dalal, Jonathan D. Schwartz, Weijing Sun, Jayne Gurtler, Mary Mulcahy, Richard S. Finn, Andrew X. Zhu
Purpose: To assess the efficacy and safety of the anti-VEGF receptor-2 (VEGFR-2) antibody ramucirumab as first-line therapy in patients with advanced hepatocellular carcinoma and explore potential circulating biomarkers.Experimental Design: Adults wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e5be34da83f5a5fba0780865eabc502
https://doi.org/10.1158/1078-0432.c.6521397
https://doi.org/10.1158/1078-0432.c.6521397
Autor:
Keith Stuart, Dan G. Duda, Francis W. Nugent, Rakesh K. Jain, Marek Ancukiewicz, Yihuan Xu, Rebecca R. Hozak, Adarsh Joshi, Rita P. Dalal, Jonathan D. Schwartz, Weijing Sun, Jayne Gurtler, Mary Mulcahy, Richard S. Finn, Andrew X. Zhu
PDF file - 143K, Kaplan-Meier survival distributions of progression-free survival, overall survival by type of antihypertensive treatment, and Time-to-event curve for first JNC 7 stage 1 or greater hypertension.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10eacab57b065662290a9aa042e1e5b9
https://doi.org/10.1158/1078-0432.22448433.v1
https://doi.org/10.1158/1078-0432.22448433.v1
Publikováno v:
Annals of surgical oncology. 29(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::66cab3986314c13e764aeac7cbf2d128
https://pubmed.ncbi.nlm.nih.gov/34117572
https://pubmed.ncbi.nlm.nih.gov/34117572
Publikováno v:
Annals of Surgical Oncology. 29:33-34
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4360f57865982d1a2aefd2edd5e1ac7e
https://doi.org/10.1245/s10434-021-10278-6
https://doi.org/10.1245/s10434-021-10278-6
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 36:e178-e182
An antimetabolite pyridine analog, 5-fluorouracil (5-FU), is used to treat solid tumors. Early toxicities may occur at standard doses of 5-FU due to dihydropyrimidine dehydrogenase (DPD) deficiency. Uridine triacetate, approved by the Food and Drug A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f0fb5beae2bfca1d07e2013366eea66
https://doi.org/10.1002/phar.1841
https://doi.org/10.1002/phar.1841
Autor:
Chris Molgaard, Frederic Gordon, Klaudia Hunter, Sebastian Flacke, Amir A. Qamar, Keith Stuart, Francis W. Nugent, Krishna S Gunturu
Publikováno v:
Journal of Clinical Oncology. 38:4586-4586
4586 Background: For HCC pts undergoing LT, loco-regional treatment as a "bridge" is standard. The best bridging modality is unclear. SBRT is safe and effective when used in pts with advanced HCC. We prospectively compared SBRT to TACE as a bridge fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32e4703629f4e317b23bcf8e32c93dc3
https://doi.org/10.1200/jco.2020.38.15_suppl.4586
https://doi.org/10.1200/jco.2020.38.15_suppl.4586